Genta/Posacon/Mometa Eardrops

Verify with FDA CVM →

139 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
139
Total Reports
1
Deaths Reported
70.0%
Death Rate

Active Ingredients

Genta/Posacon/Mometa Eardrops

Administration Routes

Auricular (Otic)TopicalUnknownOral

Species Affected

Dog 136
Cat 2
Unknown 1

Most Affected Breeds

Crossbred Canine/dog 44
Retriever - Labrador 15
Bulldog - French 10
Unknown 5
Retriever - Golden 5
Shepherd Dog - German 4
Pug 3
Pit Bull 3
Bichon Frise 3
Dog (unknown) 3

Most Reported Reactions

Lack of efficacy - NOS 37
Lack of efficacy (bacteria) - NOS 35
Lack of efficacy (fungi) - NOS 28
Deafness 12
Head shake - ear disorder 9
Ear canal inflammation 8
Lethargy (see also Central nervous system depression in Neurological) 8
Head tilt - ear disorder 8
Medication error NOS 7
Behavioural disorder NOS 6
Ear discharge 6
Ear pain 6

Outcome Breakdown

Ongoing
101 (73.2%)
Outcome Unknown
17 (12.3%)
Recovered with Sequela
13 (9.4%)
Recovered/Normal
6 (4.3%)
Died
1 (0.7%)

Data Summary

Metric Value
Total adverse event reports 139
Reports involving death 1
Case-fatality rate (reported events) 70.0%
Distinct species in reports 3
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Genta/Posacon/Mometa Eardrops Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 139 adverse event reports referencing Genta/Posacon/Mometa Eardrops, including 1 reports in which the animal died — a 70.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Genta/Posacon/Mometa Eardrops. Reported administration routes include Auricular (Otic), Topical, Unknown, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Genta/Posacon/Mometa Eardrops reports are Dog (136 reports), Cat (2 reports), Unknown (1 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (44), Retriever - Labrador (15), Bulldog - French (10) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Genta/Posacon/Mometa Eardrops are Lack of efficacy - NOS (37), Lack of efficacy (bacteria) - NOS (35), Lack of efficacy (fungi) - NOS (28), Deafness (12). Of the 138 reports with a coded outcome, Ongoing is the leading category at 73.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Genta/Posacon/Mometa Eardrops.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial